Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sean Thomas Flynn is active.

Publication


Featured researches published by Sean Thomas Flynn.


Bioorganic & Medicinal Chemistry Letters | 2000

N-1 substituted pyrimidin-4-ones: Novel, orally active inhibitors of lipoprotein-associated phospholipase A2

Helen F. Boyd; Stephen Christopher Martin Fell; Sean Thomas Flynn; Deirdre M.B. Hickey; Robert John Ife; Colin Andrew Leach; Colin H. Macphee; Kevin J. Milliner; Kitty Moores; Ivan Leo Pinto; Rod A. Porter; D. Anthony Rawlings; Stephen A. Smith; Ian Stansfield; David G. Tew; Colin J. Theobald; Caroline M. Whittaker

From two related series of 2-(alkylthio)-pyrimidones, a novel series of 1-((amidolinked)-alkyl)-pyrimidones has been designed as nanomolar inhibitors of human lipoprotein-associated phospholipase A2. These compounds show greatly enhanced activity in isolated plasma. Selected derivatives such as compounds 51 and 52 are orally active with a good duration of action.


Bioorganic & Medicinal Chemistry Letters | 2009

New quinoline NK3 receptor antagonists with CNS activity.

Paul W. Smith; Paul Adrian Wyman; Peter J. Lovell; Caroline J. Goodacre; Halina T Serafinowska; Antonio Vong; Frank P. Harrington; Sean Thomas Flynn; Daniel Marcus Bradley; Rod A. Porter; Sara A. Coggon; Graham Murkitt; Kirsten L. Searle; David R. Thomas; Jeannette M. Watson; William H. Martin; Zining Wu; Lee A. Dawson

Lead optimisation starting from the previously reported selective quinoline NK(3) receptor antagonists talnetant 2 (SB-223412) and 3 (SB-222200) led to the identification of 3-aminoquinoline NK(3) antagonist 10 (GSK172981) with excellent CNS penetration. Investigation of a structurally related series of sulfonamides with reduced lipophilicity led to the discovery of 20 (GSK256471). Both 10 and 20 are high affinity, potent NK(3) receptor antagonists which despite having different degrees of CNS penetration produced excellent NK(3) receptor occupancy in an ex vivo binding study in gerbil cortex.


Bioorganic & Medicinal Chemistry Letters | 2000

2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2.

Helen F. Boyd; Sean Thomas Flynn; Deirdre M.B. Hickey; Robert John Ife; Martin Francis Jones; Colin Andrew Leach; Colin H. Macphee; Kevin J. Milliner; D. Anthony Rawlings; Brian Peter Slingsby; Stephen A. Smith; Ian Stansfield; David G. Tew; Colin J. Theobald

Starting from two weakly active hits from high throughput screening, a novel series of 2-(alkylthio)-pyrimidin-4-ones with high potency and selectivity for lipoprotein-associated phospholipase A2 has been designed. In contrast to previously known inhibitors, these have been shown to act by a non-covalent and substrate competitive mechanism.


Bioorganic & Medicinal Chemistry Letters | 2010

The discovery of a series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles as highly brain penetrant, selective muscarinic M1 agonists.

Dale James Johnson; Ian Thomson Forbes; Steve P. Watson; Vincenzo Garzya; Graeme I. Stevenson; Graham Walker; Harminder S. Mudhar; Sean Thomas Flynn; Paul Adrian Wyman; Paul W. Smith; Graham Murkitt; Adam Lucas; Claudette Mookherjee; Jeannette M. Watson; Jane Gartlon; Andrea Bradford; Fiona Brown

A series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles are reported which were found to be potent and selective muscarinic M1 agonists. By control of the physicochemical characteristics of the series, particularly the lipophilicity, compounds with good metabolic stability and excellent brain penetration were identified. An exemplar of the series was shown to be pro-cognitive in the novel object recognition rat model of temporal induced memory deficit.


Archive | 1990

Pharmaceutical phenylpyridone derivatives

William John Coates; Sean Thomas Flynn


Archive | 1998

Bicyclic compounds as ligands for 5-ht1 receptors

Laramie Mary Gaster; Paul Adrian Wyman; Sean Thomas Flynn


Bioorganic & Medicinal Chemistry Letters | 2007

Studies on a series of potent, orally bioavailable, 5-HT1 receptor ligands-Part II

Simon E. Ward; Peter Eddershaw; Sean Thomas Flynn; Laurie J. Gordon; Peter J. Lovell; Susan H. Moore; Claire M. Scott; Paul W. Smith; Kevin M. Thewlis; Paul Adrian Wyman


Archive | 2003

Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors

Sean Thomas Flynn; Paul W. Smith; Kevin M. Thewlis; Simon E. Ward; Paul Adrian Glaxosmithkline Wyman


Bioorganic & Medicinal Chemistry Letters | 2005

Identification of a potent and selective 5-HT1B receptor antagonist

Paul Adrian Wyman; Howard R. Marshall; Sean Thomas Flynn; Ron J. King; Mervyn Thompson; Paul W. Smith; Michael S. Hadley; Gary W. Price; Claire M. Scott; Lee A. Dawson


Archive | 1989

Pyrimidine derivatives and process for their preparation

Wiliam John Coates; Sean Thomas Flynn; Derek Anthony Rawlings

Collaboration


Dive into the Sean Thomas Flynn's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge